Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 11/20 | 0.52 |
| ▸ | PARP6 | Q2NL67 | 2/20 | 0.48 |
| ▸ | PARP3 | Q9Y6F1 | 2/20 | 0.48 |
| ▸ | TNKS | O95271 | 1/20 | 0.48 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29396473 | 1.00 | PARP1 (0.52) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL25093486 | 0.89 | PARP1 (0.55) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL30064375 | 0.88 | PARP1 (0.53) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL22912763 | 0.85 | PARP1 (0.52) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL22912682 | 0.85 | PARP1 (0.52) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL29396334 | 0.85 | PARP1 (0.52) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL29394532 | 0.85 | PARP1 (0.52) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL25606984 | 0.85 | PARP1 (0.52) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL25607880 | 0.84 | PARP1 (0.49) | PARP1PARP2PARP6PARP3TNKS | |
| Hydrochloric Acid SCHEMBL28702467 | 0.84 | PARP1 (0.51) | PARP1PARP2PARP6PARP3TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372527-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2023-11-23 | — | — | US | disclosed |
| WO-2023134647-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 优领医药科技(香港)有限公司 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023088408-A1 | SELECTIVE PARP1 INHIBITOR AND APPLICATION THEREOF | 成都百裕制药股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| WO-2022074617-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |
| WO-2021013735-A1 | PARP1 INHIBITORS | ASTRAZENECA AB (SE) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372527-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | PARP12, PARP11, PARP1 | PARP1 3/4885PARP2 8/4885PARP6 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.